Skip to main content
main-content

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

share
SHARE

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis (2:54).

EULAR 2022 Congress coverage

Access the latest news and expert insight from the EULAR 2022 Congress.

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.